Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

Dual-Tracer Theranostic PET

NCT05680675
Conditions
Neuroendocrine Tumors, Prostate Cancer
Interventions
Single-Tracer FDG PET/CT Exam, Single-Tracer Cu64-DOTATATE PET/CT Exam, Single-Tracer Ga68-DOTATATE PET/CT Exam, Single-Tracer PSMA PET/CT Exam
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography
Procedure · Drug · Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer
Interventions
Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Computed Tomography, Electronic Health Record Review, Ga 68 PSMA-11, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Prostatic Neoplasm
Interventions
AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 8 more
Conditions
High-grade Glioma, Brain Metastases, Brain Metastases, Adult
Interventions
68Ga-PSMA-11 PET Scans
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
Ebrahim Delpassand
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Adenocarcinoma, Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Angiogram, Catheterization, Gallium Ga-labeled PSMA-11, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Ryan Kohlbrenner, MD
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx), Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Hepatocellular Carcinoma
Interventions
Gallium Ga 68 Gozetotide, Hepatic Artery Embolization, Positron Emission Tomography and Computed Tomography Scan
Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
Interventions
68Ga PSMA-11 injection, Positron Emission Tomography/Computed Tomography
Drug · Procedure
Lead sponsor
Dana Mathews
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype
Interventions
Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI, Quality of Life Questionnaires
Drug · Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Guided Stereotactic Body Radiation Therapy, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2Phase 3 Interventional Results available

68Ga PSMA in Preprostatectomy Patients

NCT03388346
Conditions
Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasm of Uncertain Behavior
Interventions
Ga-68 PSMA-HBED-CC PET
Drug
Lead sponsor
Michael Graham PhD, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Recurrent Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Other · Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Active, not recruiting Phase 2 Interventional Results available

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

NCT03762759
Conditions
Prostate Adenocarcinoma
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11, Positron Emission Tomography
Procedure · Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Single Photon Emission Computed Tomography, Vorinostat
Procedure · Other · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Prostatic Neoplasms
Interventions
(68Ga)PSMA-HBED-CC
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Thyroid Gland Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
1,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California